Plasmapheresis Versus Plasma Infusion From Young APOE3 Homozygotes Into MCI APOE4 Homozygotes to Slow Disease Progression
Status: | Enrolling by invitation |
---|---|
Conditions: | Cognitive Studies, Cognitive Studies |
Therapuetic Areas: | Psychiatry / Psychology |
Healthy: | No |
Age Range: | 50 - 75 |
Updated: | 3/27/2019 |
Start Date: | May 2019 |
End Date: | December 2021 |
Plasmapheresis Versus Plasma Infusion From Young APOE3 Homozygotes Into MCI APOE4 Homozygotes to Slow Disease Progression: An Unblinded Phase 1 Safety, Methodological and Exploratory Biomarkers Study.
Determine safety of plasma infusion or exchange in APOE 44 patients.
Inclusion criteria
- Patient age 50 to 75.
- APOE 44 homozygote.
- Meets the Petersen criteria for MCI (41).
- Clinical Dementia Rating (CDR) of 0.5 and Mini Mental Status Examination (MMSE) of 24
to 30 inclusive.
- Has an informant who the investigator judges has sufficient patient contact to provide
accurate information.
- Stable depression and or anxiety.
- Stable psychoactive medication for 6 weeks.
Exclusion criteria
- History of severe reaction to plasma or plasma derived products which include but not
limited to severe allergic reaction, anaphylactic reaction and transfusion related
acute lung injury (TRALI).
- Patients who do not want to receive blood transfusion for religious or cultural
reasons such as Jehovah Witness Faith.
- Has a medical condition that would interfere with participation such as congestive
heart failure (New York Heart Association Class III or IV), unstable angina, moderate
to severe renal impairment, liver failure, and poorly controlled diabetes.
- History of autoimmune disease considered clinically significant or requiring chronic
steroid or immune suppression medication.
- History of being HIV +.
- History of +VE test result indicating active hepatitis C or B (defined as both
hepatitis B surface antigen and hepatitis core antibody +VE).
- Uncontrolled hypertension as defined by systolic/diastolic BP three times more than
165/100.
- No venous access for plasma exchange therapy.
- Any neurological condition that could be contributing to cognitive decline such as
Lewy body disease, front temporal dementia, strokes or other cerebrovascular disease,
head trauma, substance abuse, multiple sclerosis, Vitamin B12 deficiency, thyroid
deficiency.
- Epileptic seizures within 10 years of screening.
- Cancer diagnosis (other than non-melanoma skin cancer) in the last 5 years.
- More than 1 subcortical stroke or more than 1 cortical stroke.
- Unable to have an MRI.
- MRI showing acute or subacute hemorrhage, evidence of normal pressure hydrocephalus,
hemispheric infarcts, glioma or other brain tumor that could contribute to cognitive
decline.
- Unstable psychiatric condition.
- On another experimental treatment study or has been on one in the last 3 months.
- If a patient consents to lumbar puncture (LP), they will be excluded from LP if any
contraindication to having an LP is present. Examples are platelet count<100,000,
spine deformity or contraindication to come off blood thinner for the LP. Patients may
still participate in the rest of the study without having and LP.
- Any unspecified reason that the investigator finds the patient unsuitable to take
part.
We found this trial at
1
site
Mayo Clinic Florida Thousands of people come to Mayo Clinic in Jacksonville, Fla., annually for...
Click here to add this to my saved trials